<DOC>
	<DOCNO>NCT01319383</DOCNO>
	<brief_summary>The purpose study compare HIV RNA expression infection within rest ( CD4 ) + cell HIV-infected patient stable ART single exposure Vorinostat ( VOR ) , exposure short interval VOR , repeat short interval exposure VOR dose several week . Hypotheses : 1 . The frequency rest CD4+ T cell- associate HIV RNA ( RCVL ) increase follow single repeat exposure VOR give appropriate interval , 2 . That repeat exposure VOR reduce frequency HIV infection within rest CD4+ T cell ( RCI )</brief_summary>
	<brief_title>The Effect Vorinostat HIV RNA Expression Resting CD4+ T Cells HIV+ Pts Stable ART</brief_title>
	<detailed_description>This Phase I-II single-center study participant ( ppts ) HIV-1 infection receive stable ART , plasma HIV RNA &lt; 50 copies/mL . Baseline ART maintain throughout study . Participants screen study entry , undergo initial leukapheresis evaluation study entry obtain rest CD4+ T cell quantitation rest CD4+ T cell infection ( RCI ) rest CD4+ T cell- associate HIV RNA ( RCVL ) baseline evaluation . All 1st time leukapheresis participant , others request base prior latent pool determination HIV-1 DNA PCR do . All participant enter study receive VOR assign study visit , undergo repeat leukapheresis measure effect VOR exposure . Participants without ex vivo response VOR ( baseline leukapheresis [ Visit 2.0 ] ) evaluate vivo response single dose VOR 400 mg . Participants complete Step 1 protocol v3.0 v5.0 eligible enroll directly Step 2 consent Version 6.0 complete Step 1 , Visits 1 2 protocol . The leukapheresis Visit 2 optional base prior ascertainment baseline parameter . Omission leukapheresis visit 2 determine study PI . Enrollment completion require research assay complete study visit . Enrollment Step 1 continue 12 evaluable participant successfully complete multiple dos VOR ( Step 3 ) , study-stopping rule meet . Step 1 include four visit : screening ( visit 1 ) , enrollment baseline Leukapheresis ( Visit 2 ) , single dose administration VOR ( visit 3 ) safety follow ( Visit 4 ) . It estimate 30 eligible participant may screen enrol provide total 12 evaluable participant complete Step 3 . VOR 400 mg administer single dose study Visit 3 . Each participant receive 400 mg VOR one time point . An abbreviated pharmacokinetics ( PK ) well leukapheresis procedure part Visit 3 . It anticipate Step 1 occur minimum 8 week . All participant must complete Step 1 prior move Step 2 . All participant assess Visit 3 leukapheresis vivo response 400 mg VOR . Progression Step 1 ( single dose ) Step 2 ( paired dos ) base participant 's increase RCVL follow first dose 400 mg VOR ( Visit 3 ) , compare measure baseline ( Visit 2 ) . Progression Step 2 ( paired dos ) Step 3 ( multiple dos ) base participant 's increase RCVL follow 3rd dose 400 mg VOR ( Visit 6 ) , compare measure baseline ( Visit 2 ) . The goal study determine optimal interval two dos VOR ( Step 2 ) , response RCI ( secondarily RCLV ) repeat dos interval ( Step 3 ) . Step 2 initiate least 4 week completion Step 1 safety follow visit ( Visit 4 ) . If great 60 day elapse Visit 4 Visit 5 , participant repeat screen Visit lab qualify continue study participation . In Step 2 , two paired dos VOR 400 mg administer . The interval 2 paired dos short 48 hour , much 4 day apart , participant assess via 3rd leukapheresis vivo response second paired dos 400 mg VOR . The first three ( 3 ) participant first assess in-vivo response 2nd dose paired dos give 48 hour ( 2 day ) apart . Subsequent participant assessed response pair dos separate 48 hour , interval may lengthen much 96 hour ( 4 day ) , dictate accumulated response observe subsequent participant . If least 2 3 participant 48-hour interval respond ( defined significant within-subject increase cell-associated HIV RNA , see Fig 3 ) , 3 subsequent participant receive 48-hour interval . If 2 3 respond 4 6 total ) , 3 additional participant receive 48-hour interval . If among first 6 evaluable participant receive 48-hour interval 3 non-responders , subsequent participant receive 72-hour interval . Participants receive 72-hour interval assess way receive 48-hour interval , either continue additional participant 72-hour interval increase 96-hour interval . Step 2 enroll total 12 evaluable subject measureable increase cell-associated HIV RNA obtain , volunteer advance Step 3 . Our preliminary result version 5.0 consistent hypothesis complex cellular effect HDAC inhibitor exposure require 24 hour resolve . We observe appear antagonistic effect VOR dose blunts effect next dose two dos give within 24 hour . The purpose Step 2 establish optimal dose interval response Vorinostat sustain . Step 2 study dose interval ; start 48-hour interval move long interval dos depend effect observe ultimate goal determine short interval yield optimal effect VOR . If participant fail respond initial Step 2 dose interval , eligible repeat Step 2 . They re-enter repeat Step 2 one time . They re-enter Step 2 test longer dose interval . Again , &gt; 60 day elapse final safety visit step 2 ( Visit 7 ) re-entry Step 2 , re-screen ( visit 1 ) qualify continue study . After period least 6 week , allow data analysis , participant demonstrate vivo response 2nd pair dose VOR proceed Step 3 receive 10 dos VOR 400 mg administer interval cell-associated HIV-RNA induction observe Step 2 . If great 60 day elapse Visit 7 Visit 8 , participant repeat screen visit lab qualify continued participation study . At completion 10 dos , participant assess via 4th final leukapheresis vivo response serial dosing VOR . It anticipate Step 3 occur minimum 4 week ; however may vary among participant base Step 2 dose interval stage . Accumulated blood volume time leukapheresis procedure determine length time stepsParticipants complete protocol ( version 6.0 ) , respond initially Step 2 receive total 5200 mg Vorinostat . Participant complete study , repeat Step 2 , receive total 6000 mg Vorinostat . For reference , participant complete previous version ( 5.0 ) receive total 10,000 mg Vorinostat without clear evidence durable drug-associated toxicity thus far . The change frequency HIV-1 infection per million rest CD4 + cell measure repeat short interval dose VOR Step 3 . This 4th leukapheresis ( Visit 12 ) compare baseline leukapheresis do Visit 2 . If VOR 400 mg dose Step 3 interrupt due toxicity intolerance , leukapheresis perform soon possible VOR interruption . This justified depletion rest cell infection occur ; new rest cell infection unlikely occur presence ART . Test dose Step continue study 's stopping ( lack response five ) toxicity rule meet .</detailed_description>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>1 . HIV1 infection 2 . Men , woman age ≥18 year . 3 . Ability , willingness give write informed consent . 4 . Able , willing provide adequate locator information . 5 . Karnofsky performance status &gt; 70 . 6 . Able , willing adhere therapy adherent ART . 7 . Able , willing comply time requirement study visit evaluation . 8 . On potent ART , define least 2 nucleoside/nucleotide reverse transcriptase inhibitor plus nonnucleoside reverse transcriptase inhibitor , integrase inhibitor , protease inhibitor without interruption ( define miss dos two consecutive day four cumulative day ) 24 week immediately prior entry . Other potent fully suppressive antiretroviral combination consider casebycase basis . Prior change elimination medication easier dose schedule , intolerance , reason permit alternative suppression regimen maintain . 9 . Adequate vascular access leukapheresis . 10 . Able swallow pill without difficulty . 11 . On combination ART ≥ 18 month prior study entry , consecutive HIV1 RNA value &gt; 50 copies/mL time period 12 . CD4 cell count ≥ 300 cells/µl screening . 13 . All male study volunteer must agree participate conception process . 14 . Must seronegative Hep C RNA , Hep B sAg within 90 day entry 15 . Must adequate organ function indicate follow lab value : Hematological : Absolute Neutrophil Count ( ANC ) ≥ 1,500/mcL Platelets ≥ 125,000/mcL Hgb ≥ 12 g/dL Coagulation : Prothrombin Time International Normalized Ratio ( INR ) ≤ 1.5x upper limit normal ( ULN ) Chemistry : K+ level Within normal limit Mg++ level &gt; Lower limit normal ( LLN ) &lt; 1.5 x ULN Glucose Screening serum glucose ( fasting/nonfasting ) 120 mg/dl . Renal : Serum creatinine/calculated creatinine clearance* ≤ 1.3 X ULN OR ≥ 60 mL/min participant creatinine level &gt; 1.3 X ULN Hepatic : Serum total bilirubin Total bilirubin &lt; 1.5 time ULN . If total bilirubin elevate , direct bilirubin measure participant eligible direct bilirubin &lt; 2 X ULN . Aspartate amino transferase ( AST ) ( SGOT ) Alanine amino transferase ( ALT ) ( SGPT ) ≤ 2.0 X ULN Lipase &lt; 1.6 X ULN Alkaline Phosphatase ≤ 2.5 X ULN *Creatinine clearance calculate per institutional standard . 1 . Received blood transfusion hematopoetic growth factor within 90 day . 2 . All woman unless write documentation menopause ( absence period ≥ one year ) , hysterectomy , oophorectomy , tubal ligation . 3 . The study PI unable construct fully active alternative regimen base previous resistance test and/or treatment history 4 . Use atazanavir raltegravir background antiretroviral regimen . 5 . Any antiretroviral medication coadministered Vorinostat within 4 week first Vorinostat dose anytime thereafter study . 6 . Use follow within 90 day prior entry : systemic cytotoxic chemotherapy ; investigational agent ; immunomodulators ( colonystimulating factor , growth factor , systemic corticosteroid , HIV vaccine , immune globulin , interleukin , interferon ) ; coumadin , warfarin , Coumadin derivative anticoagulant . 7 . Any serious illness require systemic treatment hospitalization , subject must either complete therapy clinically stable therapy , opinion site investigator , least 90 day prior entry . 8 . Compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric illness physical illness , e.g. , infectious disease . Prisoner recruitment participation permit . 9 . Treatment active AIDSdefining opportunistic infection within 90 day prior screen . 10 . Any history cardiac rhythm disturbance require medical surgical therapy . 11 . Any history acute chronic pancreatitis . 12 . Use following medication carry risk torsades de pointes : amiodarone , arsenic trioxide , astemizole , bepridil , chloroquine , chlorpromazine , cisapride , clarithromycin , disopyramide , dofetilide , domperidone , droperidol , erythromycin , halofantrine , haloperidol , ibutilide , levomethadyl , mesoridazine , methadone , pentamidine , pimozide , probucol , procainamide , quinidine , sotalol , sparfloxacin , terfenadine , thioridazine . 13 . Receipt compound HDAC inhibitorlike activity , valproic acid within last 30 day . Potential participant may enroll 30day washout period . 14 . Known hypersensitivity component VOR analog . 15 . Known psychiatric substance abuse disorder would interfere cooperation requirement trial . 16 . Pregnancy breast feeding , expect father child within project duration study . 17 . Inability communicate effectively study personnel .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>HIV-1 Infection</keyword>
	<keyword>HIV RNA &lt; 50 copies/mL</keyword>
	<keyword>Stable ART</keyword>
	<keyword>Resting CD4+ T cell</keyword>
	<keyword>Leukapheresis</keyword>
	<keyword>Vorinostat</keyword>
	<keyword>HIV RNA expression</keyword>
	<keyword>PK visit</keyword>
</DOC>